DrugPatentWatch Database Preview

TAKEDA Company Profile

TAKEDA has twenty-one approved drugs.

There are eighty-three US patents protecting TAKEDA drugs.

There are one thousand and seventy-one patent family members on TAKEDA drugs in fifty-eight countries and one hundred and eight supplementary protection certificates in fifteen countries.

International Patents:	1071
US Patents:	83
Tradenames:	22
Ingredients:	16
NDAs:	21
Patent Litigation for TAKEDA:	See patent lawsuits for TAKEDA
PTAB Cases with TAKEDA as patent owner:	See PTAB cases with TAKEDA as patent owner

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-001	Jan 25, 2013		RX	Yes	No	7,807,689	➤ Try a Free Trial	Y	Y		➤ Try a Free Trial
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-001	Sep 30, 2013		RX	Yes	No	9,125,908	➤ Try a Free Trial				➤ Try a Free Trial
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009		RX	Yes	Yes	7,361,676	➤ Try a Free Trial	Y			➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ACTOS	pioglitazone hydrochloride	TABLET;ORAL	021073-003	Jul 15, 1999	6,150,383	➤ Try a Free Trial
Takeda Pharms Usa	ACTOS	pioglitazone hydrochloride	TABLET;ORAL	021073-001	Jul 15, 1999	4,444,779	➤ Try a Free Trial
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009	7,919,116	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	15 mg/1000 mg and 30 mg/1000 mg	➤ Subscribe	2011-09-23
➤ Subscribe	Tablets	0.6 mg	➤ Subscribe	2011-12-23
➤ Subscribe	Tablets	12.5 mg/500 mg and 12.5 mg/1000 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Tablets	8 mg	➤ Subscribe	2009-07-22
➤ Subscribe	Tablets	40 mg and 80 mg	➤ Subscribe	2013-02-13
➤ Subscribe	Delayed-release Orally Disinte	15 mg and 30 mg	➤ Subscribe	2006-12-27
➤ Subscribe	Delayed-release Capsule	30 mg	➤ Subscribe	2010-11-30
➤ Subscribe	Tablets	15 mg/500 mg and 15 mg/850 mg	➤ Subscribe	2008-03-06
➤ Subscribe	Tablets	30 mg/2 mg and 30 mg/4 mg	➤ Subscribe	2009-12-22
➤ Subscribe	Tablets	6.25 mg, 12.5 mg and 25 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Tablets	5 mg, 10 mg, 15 mgand 20 mg	➤ Subscribe	2017-10-02
➤ Subscribe	Delayed-release Pellets/Capsul	15 mg and 30 mg	➤ Subscribe	2005-12-05
➤ Subscribe	Capsule	60 mg	➤ Subscribe	2010-08-25

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1436271	92397	Luxembourg	➤ Try a Free Trial	PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE
1586571	2014C/010	Belgium	➤ Try a Free Trial	PRODUCT NAME: ALOGLIPTINE (EN TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/13/844/001 20130923
1436271	2014/022	Ireland	➤ Try a Free Trial	PRODUCT NAME: VORTIOXETINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/891 20131220
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.